Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spruce Biosciences, Inc. - Common Stock (NQ: SPRB )

0.1399 +0.0070 (+5.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,268,162
Open 0.1346
Bid (Size) 0.1397 (143)
Ask (Size) 0.1399 (1)
Prev. Close 0.1329
Today's Range 0.1280 - 0.1400
52wk Range 0.1100 - 0.8700
Shares Outstanding 40,710,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which stocks have an unusual volume on Monday?
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
On Thursday, there are stocks with unusual volume. Let's take a look.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill

Performance

YTD
-66.64%
-66.64%
1 Month
-57.59%
-57.59%
3 Month
-62.94%
-62.94%
6 Month
-74.38%
-74.38%
1 Year
-80.05%
-80.05%

More News

Read More
These stocks have an unusual volume in today's session
Via Chartmill
Top stock movements in today's session.
Via Chartmill
Tuesday's session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
The market is filled with gapping stocks in Tuesday's session.
Via Chartmill
Crude Oil Moves Lower; Citigroup Posts Upbeat Results
Via Benzinga
Exposures Fossil Fuels
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
Nasdaq Surges 100 Points; Bank of America Earnings Top Views
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
Via Benzinga
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Spruce Biosciences, Inc.
Via Business Wire
SPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
Spruce Biosciences Recognized as a Bay Area Best Place to Work
From Spruce Biosciences, Inc.
Via Business Wire
Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder
Via Benzinga
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
From Spruce Biosciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.